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IS FETAL FIBRONECTIN (fFN) A MARKER OF INTRA-AMNIOTIC INFLAMMATION IN  
PATIENTS WITH MIDTRIMESTER SHORT CERVIX? 
DANIEL KIEFER, MD1, SEAN KEELER, MD2, ORION RUST, MD3, MICHAEL DEMISHEV, MD1, JOLENE MUSCAT, MD1, ERAN BORNSTEIN, MD4, NAZEEH HANNA, MD5
Table 1. Baseline Characteristics
1Stony Brook-Winthrop University Hospitals, Long Island, New York; 2Naval Medical Center Portsmouth, Portsmouth, Virginia; 3Lehigh Valley Health Network, Allentown, Pennsylvania;  
4New York University School of Medicine, New York, New York; 5Winthrop University Hospital, Mineola, New York
Variable fFN Negative (N=56)
fFN Positive 
(N=30) P Value *
Demographic Characteristics †
Maternal Age (yrs) 25 (16-41) 29 (16-41) 0.10
Gestational Age at Admission 
(weeks) 20 (16-24) 20 (17-23) 0.40
Clinical Characteristics†
Cervical Length (mm) 15 (1-25) 13 (0-25) 0.50
AF Glucose 35 (20-75) 41 (10-60) 0.19
AF WBC Count 24 (1-950) 21 (0-1150) 0.56
* Wilcoxon Rank-Sum
† Data are presented as median (range)
Table 2. Comparison of Cytokine Levels by fFN Status
Cytokine
FFN Negative N=56 FFN Positive N=30
P Value *
Median Range Median Range
IL-1β 0.8 0.8-13.2 1.0 0.8 – 780.1 0.029
Il-1ra 4050.2 1.4- 9691.8 4726.0 1.4 – 29929.7 0.103
IL-2 1.1 1.1 – 45.5 1.1 1.1 – 19.4 0.196
IL-4 0.5 0.5 – 2.5 0.6 0.5 – 4 0.764
IL-5 0.8 0.8 – 0.8 0.8 0.8 – 2 0.006
IL-6 351.5 1.1 – 4131.9 417.3 1.1 – 25903 0.052
IL-7 3.1 0. – 13.9 4.1 0.5 – 11 0.082
IL-8 267.9 0.5 – 6797.0 468.7 0.5 – 25022.3 0.065
IL-9 14.1 0.7 – 46.2 17.0 0.7 – 76 0.342
IL-10 0.9 0.9 – 521.4 0.9 0.9 – 869.4 0.297
IL-12 0.5 0.5 – 10.1 0.8 0.5 – 21.3 0.005
IL-13 2.1 2.1 – 4.7 2.1 2.1 – 4.3 0.634
IL-15 5.8 4.2 – 30.2 6.7 4.2 – 29.9 0.577
IL-17 0.2 0.2 – 60.7 0.2 0.2 – 79.8 0.286
Eoxatin 14.6 14.6 – 178.1 15.2 14.6 – 142.2 0.258
G-CSF 170.6 1.1 – 8216 215.0 1.1 – 15059.2 0.590
IFN-γ 67.5 19.3 – 1188.1 105.0 19.3 – 690.9 0.054
IP-10 11074.5 6.5 – 118257.5 34868.8 58.9 – 148778.1 0.006
MCP-1 336.5 6.7 – 5327.9 570.2 6.7 – 3955.3 0.025
MIP-1α 2.4 2.4 – 301.0 2.4 2.4 – 362.9 0.050
MIP-1β 36.6 1.1 – 1634.6 69.4 1.1 – 1721 0.007
PDGF-bb 237.7 1.0 – 5554.8 275.9 57.0 – 1617.5 0.379
RANTES 17.3 1.2 – 7072.1 22 1.5 - 8743.0 0.475
TNF-α 3.0 3.0 – 69.0 3.0 3.0 – 143.2 0.216
VEGF 1.6 0.5 – 56.2 7.0 0.5 – 114 0.131
*Bonferroni correction; P<0.002 required for significance
Key: Interleukin (IL), granulocyte colony stimulating factor (G-CSF), interferon gamma (IFN-γ), inducible protein-
10 (IP-10), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein (MIP), platelet derived 
growth factor (PDGF), tumor necorsis factor alpha (TNF-α), regulated on activation normal T cell expressed and 
secreted (RANTES), and vascular endothelial growth factor (VEGF)
